AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04301895
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 minute remifentanil infusion
Trial: NCT01441635
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets
Trial: NCT01441635
Drug: Estradiol/Norethindrone acetate (E2/NETA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A continuous once-daily oral tablet containing estrogen and progestin; the low-dose strength contains estradiol 0.5 mg and norethindrone acetate 0.1 mg.
Trial: NCT01441635
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.0 mg micronized estradiol tablets administered once a day
Trial: NCT02683785
Drug: GSK3196165
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3196165 will be supplied as a liquid and will be administered as a subcutaneous injection. The drug will be administered weekly for 5 injections, then every other week for 3 further injections.
Trial: NCT02683785
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered as above.
Trial: NCT02299947
Drug: Haemocomplettan P
RxNorm normalized name: P & S
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02299947
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02489240
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 IU placebo tablets were taken daily for 6 days
Trial: NCT02713477
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Trial: NCT00759772
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sc daily for 6 months
Trial: NCT02866032
Drug: MOB015B
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01305408
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets, taken orally, once daily in the morning
Trial: NCT00600743
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug one trial vs placebo
Trial: NCT04299633
Drug: Calcium acetate
RxNorm normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 x 667 mg oral gelcaps
Trial: NCT04299633
Drug: Auryxia®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 1 gram tablets (210 mg ferric iron equivalent to 1000 mg ferric citrate)
Trial: NCT02869113
Drug: BAY 98751 (Y65-102)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 µL in one eye
Trial: NCT02869113
Drug: BAY 98751 (Y65-106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 µL in one eye
Trial: NCT02869113
Drug: Standard shampoo mixture (Control)
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 µL in other eye
Trial: NCT00842244
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally twice daily for 14 days followed by 7 days of drug free period. Starting dose is 1000mg/m\^2 twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
Trial: NCT05015673
Drug: SEP363856
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05015673
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02084199
Drug: GLPG0634
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral tablet, intake once daily for 10 days
Trial: NCT01436253
Drug: Hypolipemics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological measures at the discretion of the treating physician and in accordance with the respective authorized label and European Guidelines on the Management of Hypercholesterolemia accepted by the Croatian Society of Cardiology.
Trial: NCT01406470
Drug: Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG-SN™ 10g/200mL, dose is 300-900 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with IVIG-SN™ will be 12 months with a 3 month follow-up.
Trial: NCT00825149
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered as per schedule specified in the respective arm.
Trial: NCT00825149
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin will be administered as per schedule specified in the respective arm.
Trial: NCT00413205
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po daily
Trial: NCT00623805
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine was supplied as film-coated tablets.
Trial: NCT04536129
Drug: Hydrocortisone (CORTIVIS ®)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Once enrolled all the patients had to instill topical low dose (1,005 mg) preservative-free hydrocortisone (CORTIVIS ®- Medivis, Catania, Italy) 2 times daily in each eye for two weeks.
Trial: NCT01200290
Drug: LY2127399
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 milligrams (mg) administered subcutaneously every 4 weeks for 20 weeks. A loading dose of 240 mg will be given as the first dose of the study medication
Trial: NCT01144377
Drug: LY2541546
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT01144377
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT00925678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00099749
Drug: FTY 720
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01304082
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml subcutaneous injection 0.9% sodium chloride, given once
Trial: NCT02397460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03848039
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration by intramuscular injection of the placebo according to vaccination schedule of the 9-valent HPV vaccine (0, 2, 6 months)
Trial: NCT02213055
Drug: Standard Head lice product
RxNorm normalized name: Head & Shoulders Shampoo Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The most common treatments are pesticide-based, over-the-counter remedies of permethrin (1%), or pyrethrin-based products.After baseline scalp exam for lice count and preexisting signs of irritation, parents who agree to the comparison arm may purchase any other head lice treatment of their choice. All treatments are to be done at home by a parent or guardian. All participants will be examined for lice count and scalp irritation the day after the first application, and one and two weeks after the first application. Participants may also be examined by parents or the school nurse at any time if signs of irritation or re-infestation occur. If the child is still found to be infested during any examination, the school nurse will instruct the parent/guardian to retreat.
Trial: NCT00999973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01907776
Drug: ME1100 inhalation solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ME1100 inhalation solution (arbekacin for oral inhalation at 150mg/mL), 0.6, 2.0, 3.0, 4.0, 6.0, or 9.0mL, Single Dose
Trial: NCT01907776
Drug: ME1100 placebo inhalation solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle placebo
Trial: NCT02671760
Drug: Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-drug combination comprised of 5 mg zolpidem and 0.5 mg lorazepam
Trial: NCT02671760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02191384
Drug: Orcinoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, twice per day
Trial: NCT03349619
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this arm will receive nasal saline solution 0.9%, two sprays per nostril, three times/day for 4 weeks
Trial: NCT01556763
Drug: EVP-6124 (0.3 mg/day)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.
Trial: NCT01556763
Drug: EVP-6124 (1.0 mg/day)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.
Trial: NCT01556763
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo was administered as one capsule per day for 21 days.
Trial: NCT01556763
Drug: Antipsychotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapy with antipsychotic medication (aripiprazole \[10 to 30 mg/day\], olanzapine \[10 to 20 mg/day\], paliperidone \[3 to 12 mg/day\], or risperidone \[2 to 16 mg/day\]), taken at the same time each day as the EVP-6124 dose. Patients must have been taking concomitant therapy for at least 2 weeks at a stable dose to be eligible for the study.
Trial: NCT00132899
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate and infliximab combination
Trial: NCT00132899
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and infliximab combination therapy.
Trial: NCT00159263
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry powder inhaler
Trial: NCT00174694
Drug: Telithromycin
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00570284
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally administered panobinostat at 20 mg twice weekly (core phase); orally administered panobinostat 45 mg twice weekly if 20 mg twice weekly was tolerated in Cycle 1 (extension phase)
Trial: NCT00088933
Drug: recombinant fowlpox-CEA(6D)/TRICOM vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intradermally
Trial: NCT00918879
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet, once daily for 24 weeks
Trial: NCT01205022
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01205022
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01431820
Drug: Vehicle Solution
RxNorm normalized name: compounding vehicle solution sugar free no. 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical
Trial: NCT00138229
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00565812
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets once a day for 2 years
Trial: NCT00865111
Drug: Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
Trial: NCT04374500
Drug: Vasodilators in CAD patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This applies only to protocol 3
Trial: NCT02426112
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02426112
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04441424
Drug: Hydroxychloroquin with Azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group of COVID-19 patients were given the conventional therapy approved in Iraq for COVID-19, namely Hydroxychloroquine 400mg PO twice per day for 5 days and Azithromycin once PO 500 mg per day for 5 days.
Trial: NCT03854812
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: loading of 1 mcg/kg in over 15 minutes of fentanyl then will receive continuous infusion starting at 1 ml /kg/h. of 0.5 mcg/ml solution
Trial: NCT00666900
Drug: Low Strength IDP-107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day for 12 weeks
Trial: NCT00666900
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day for 12 weeks
Trial: NCT00601263
Drug: Anti-Asthma Herbal Medical Intervention (ASHMI)
RxNorm normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We propose to test 3 daily doses in which 2,4, or 6 ASHMI or placebo capsules will be administered orally twice daily (BID) for 7 days.
Trial: NCT00234702
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01225276
Drug: NewGam 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam . The maintenance doses to be infused 7 times will be 2.0 g/kg every 21 (+/-4) days.
Trial: NCT01225276
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose at baseline (Week 0) in Placebo arm will be corresponding volume of an authorised 0.9% saline solution . The maintenance doses of the 0.9% saline solution to be infused 7 times will be given every 21 (+/-4) days.
Trial: NCT01225276
Drug: NewGam 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms. The maintenance doses to be infused 7 times will be 1.0 g/kg every 21 (+/-4) days.
Trial: NCT01365936
Drug: HMG
RxNorm normalized name: HMG-CoA reductase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this prospective trial, women with PCOS (according to Rotterdam criteria) were randomized (80 patients) after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
Trial: NCT01225276
Drug: NewGam 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms. The maintenance doses to be infused 7 times will be 0.4 g/kg every 21 (+/-4) days.
Trial: NCT01228318
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1. A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.~2. A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes.
Trial: NCT03867695
Drug: sterile saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a placebo injection with 0,5 mL/kg of sterile normal solution
Trial: NCT04393194
Drug: Vaginal Cream with Applicator [Dose Form]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with symptomatic POP will be assigned as outpatients. After the initial pessary fitting, the patients will be followed up in 2 weeks. If the prolapse is supported, no discomfort, and the patient decides to continue to use the pessary, the pessary fitting is successful. Patients with successful ring pessary fitting, who agree to participate and sign written consent, will be randomized into the vaginal estrogen group and the placebo group. The patients will be followed up every 3 months after wearing pessary combined with vaginal medication, until 1 year after wearing the pessary.
Trial: NCT03011567
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive acetaminophen for postpartum mild pain relief
Trial: NCT03011567
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive ibuprofen for postpartum mild pain relief
Trial: NCT00603525
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mL sterile, pyrogen free 0.9% NaCl. A treatment cycle consisting of two IV infusion taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
Trial: NCT02686177
Drug: Metformin or sulfonylurea
RxNorm normalized name: metformin and sulfonylureas
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00218114
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be on matching placebo.
Trial: NCT03561298
Drug: BGB-3111 and Drug Cocktail
RxNorm normalized name: BLOOD AND BLOOD FORMING ORGAN DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGB-3111 and Drug Cocktail (midazolam, warfarin, omeprazole, digoxin and rosuvastatin)
Trial: NCT01784120
Drug: Doxorubicin/Genexol-PM
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00615875
Drug: naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: opaque pale orange suspension: 20mL q12h x 4 doses mixed in juice.
Trial: NCT00615875
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: opaque pale orange suspension: 20mL q12h x 4 doses mixed in juice
Trial: NCT01941173
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01941173
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00128245
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02513992
Drug: 99m-Technetium Ethyl Cysteinate Dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of perfusion tracer 99m Tc-ECD during epileptic seizure
Trial: NCT00219700
Drug: Ibuprofen-PC
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04371666
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo per schedule specified in the arm description
Trial: NCT03433677
Drug: LY900014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by CSII
Trial: NCT00750295
Drug: SBR759
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
Trial: NCT04371666
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic deflazacort or equivalent potency of corticosteroids administered orally
Trial: NCT02330419
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04348786
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycylcine 100 mg bid ,esomprazole 20 bid,Bismuth subsalicylate 262 tab.2 tab q.i.d,Tinadizole 500 bid
Trial: NCT01041404
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg/m2 i.v. infusion on Days 1 through 5 of cycle every 3 weeks for 6 cycles
Trial: NCT01041404
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles
Trial: NCT02750449
Drug: Sun screening Sport Lotion, (BAY987516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μl/ cm\*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3 μl/ cm\*2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. (Formulation Number - RB# Y65-110)
Trial: NCT00785811
Drug: Placebo L-arginine aspartate (Targifor)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of L-arginine taken orally in a single daily dose for 8 weeks
Trial: NCT02936843
Drug: Salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 gram, 3 times daily by mouth (total of 3 grams daily)
Trial: NCT02936843
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Salsalate; 2 Tabets, 3 times daily by mouth (total of 3 grams daily)
Trial: NCT01025830
Drug: Zerit/Epivir/Viramune
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stavudine (40mg) Lamivudine (150mg) and Nevirapine (200mg) All taken twice daily.
Trial: NCT04411329
Drug: Hyalouridinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hyalouridinase
Trial: NCT03293524
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is a BSS, sterile, apyrogenic solution and used for ocular surgery. The placebo will be administered via intravitreal injection in a volume of 90 μL.
Trial: NCT00384189
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide placebo-matching inhaler